AstraZeneca Pharma India Ltd.

AstraZeneca India Secures Regulatory Approval for Novel Hyperkalaemia Treatment Lokelma

3 months ago

• AstraZeneca Pharma India has received CDSCO approval to import and market sodium zirconium cyclosilicate (Lokelma) for treating high potassium levels in adult patients. • The approved formulation will be available in 5g and 10g doses as an oral suspension powder, expanding treatment options for hyperkalaemia management in India. • This regulatory milestone follows AstraZeneca's earlier approval for Durvalumab (Imfinzi) in cancer treatment, demonstrating the company's expanding presence in the Indian pharmaceutical market.

AstraZeneca's Durvalumab-Tremelimumab Combination Approved for Liver Cancer Treatment in India

3 months ago

• India's CDSCO grants AstraZeneca approval to import and distribute Durvalumab (Imfinzi) for unresectable hepatocellular carcinoma treatment in combination with Tremelimumab. • The regulatory authorization covers Durvalumab solution for infusion in two formulations: 120 mg/2.4 ml and 500 mg/10 ml, expanding treatment options for liver cancer patients. • This new indication approval marks a significant advancement in India's liver cancer treatment landscape, pending final statutory approvals for market distribution.

AstraZeneca's Durvalumab Receives Indian Approval for Expanded NSCLC Treatment

8 months ago

• AstraZeneca Pharma India has received CDSCO approval to import and distribute durvalumab for an additional indication in India. • The approval covers the use of durvalumab with chemotherapy as neoadjuvant treatment, followed by durvalumab monotherapy after surgery. • This expands durvalumab's use to treat resectable non-small cell lung cancer (NSCLC) with tumors 4 cm or larger and/or node-positive cases. • Lung cancer is a significant cause of cancer-related mortality in India, with a notable portion having resectable NSCLC.